Research
Hormonal
Oral semaglutide (up to 14 mg daily) significantly reduces liver steatosis, liver enzymes, and body weight in patients with NAFLD and Type 2 Diabetes, correlating with weight loss.
Oral semaglutide (up to 14 mg daily) is an effective treatment for NAFLD in patients with Type 2 Diabetes, significantly reducing liver fat and enzymes. The benefits are closely linked to weight loss, and side effects are generally manageable with dose escalation.
ModerateSupportsMEDIUM confidence
Body weight, AST, HbA1c, γ-GT, ALT and plasma glucose decreased significantly from baseline to 12 weeks (p<0.001 for the first four parameters, p < 0.01 for the last two) and these changes remained until the end of the study... Levels of the HOMA-IR and serum triglyceride were also significantly reduced at 24 weeks (p < 0.01 and p < 0.05, respectively). Moreover, CAP values decreased from baseline to 24 weeks (p < 0.01). Interestingly, changes in body weight were significantly correlated with those in ALT (r = 0.52, p < 0.05) and CAP (r = 0.72, p < 0.01).
Why this rating
Based on a single-arm, open-label pilot study with a small sample size (n=16) and no control group.
Source
Evolving role of semaglutide in NAFLD: in combination, weekly and oral administration
Evgenia Koureta et al. · Frontiers in Pharmacology · 2024
DOI 10.3389/fphar.2024.1343587
narrative_reviewCited 10×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Weekly subcutaneous semaglutide (up to 2.4 mg) significantly reduces liver steatosis and liver enzymes in patients with NAFLD/NASH, but does not significantly improve liver fibrosis or achieve NASH resolution compared to placebo in patients with compensated cirrhosis.Good
- Combining semaglutide with cilofexor or firsocostat improves liver steatosis more than semaglutide monotherapy in patients with NASH and mild-to-moderate fibrosis, without significantly affecting liver stiffness.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →